Status:
COMPLETED
Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis
Lead Sponsor:
CAMC Health System
Conditions:
MRSA Infections
Eligibility:
All Genders
18-90 years
Brief Summary
This study prospectively selects the patients to examine the effectiveness of the investigators' current standard of prophylaxis prior to vascular surgery and to compare the effectiveness of vancomyci...
Detailed Description
According to Medqic.org (site for the Surgical Care Improvement Project) the current recommended drug of choice for prophylaxis prior to vascular surgery is Cefazolin (Ancef). The exception would be t...
Eligibility Criteria
Inclusion
- Patients greater than 18 years of age undergoing vascular surgery including carotid procedures and a vascular access procedure (Fistula or Graft).
Exclusion
- Patients with an allergy to daptomycin or vancomycin.
- Patients with chronic wounds.
- Prior colonization of MRSA.
- Increased MRSA rate facility wide.
- Continuous inpatient stay \>27 hrs prior to surgical procedure.
- Patients with active infection requiring antibiotics preoperatively.
- Patients with a history of MRSA colonization or infection, HIV, admission for \>3 months in an acute care center or long-term care center, penicillin allergy or penicillin allergy and on dialysis.
- Dialysis patients.
Key Trial Info
Start Date :
August 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
169 Patients enrolled
Trial Details
Trial ID
NCT00967941
Start Date
August 1 2007
End Date
August 1 2010
Last Update
February 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Vascular Center of Excellence
Charleston, West Virginia, United States, 25304